Clinical Trials | June 14, 2024
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Subscribe To Our Newsletter & Stay Updated
